Lexaria Updates Business Development
Lexaria Updates Business Development
Lexaria's Human Study GLP-1-H26-7 Has Begun Dosing on Schedule
Lexaria's Human Study GLP-1-H26-7 has Begun Dosing on Schedule
Lexaria's Animal Study GLP-1-A26-1 has Begun Dosing on Schedule
Lexaria's Animal Study GLP-1-A26-1 Has Begun Dosing on Schedule
GLP-1 "Arms Race" Intensifies as the Addressable Markets Continue to Expand
GLP-1 'Arms Race' Intensifies as the Addressable Markets Continue to Expand
Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway
Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway.
Lexaria Attending the BIO International Convention, as Part of a Broader Business Development Program
Lexaria Attending the BIO International Convention, as part of a Broader Business Development Program
Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #7
Lexaria Bioscience Releases Second Episode of Investor Video Series
Lexaria Bioscience Releases Second Episode of Investor Video Series
Lexaria Updates Progress on Human Study #7
Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications
Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications
Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended
Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended
Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs
Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs
Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales
Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales
Lexaria's New Animal Study Aims to Expand Valuable Intellectual Property
Lexaria's New Animal Study Aims to Expand Valuable Intellectual Property
Lexaria Applauds Eli Lilly's Foundayo(TM) Drug Approval
Lexaria Applauds Eli Lilly's Foundayo(TM) Drug Approval
Lexaria to Begin New Human Clinical Study in GLP-1
Lexaria to Begin New Human Clinical Study in GLP-1
Lexaria's Robust Patent Portfolio Continues to Grow
Lexaria's Robust Patent Portfolio Continues to Grow
Lexaria's Oral GLP-1 Drug Strategy Validated by Industry
Lexaria's Oral GLP-1 Drug Strategy Validated by Industry
Lexaria Announces New R&D Plans for 2026
Lexaria Announces Positive Final Results From Human Pilot Study #5
Lexaria Awarded Six Additional Patents
Lexaria Awarded Six Additional Patents
Lexaria Releases Annual Letter from the CEO
Lexaria Releases Annual Letter from the CEO
Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4
Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4
Lexaria Says Oral GLP-1 Cuts Side Effects Nearly 50% Versus Novo Nordisk's Rybelsus
Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4
Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4
Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules